The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy

Area of Science:

• Oncology
• Chronobiology
• Genomics

Background:

• Cancer chronotherapy aims to maximize anti-tumor effects and minimize toxicity by synchronizing treatment with circadian rhythms.
• A comprehensive understanding of clock gene alterations and their clinical significance in various cancers is currently lacking.

Purpose of the Study:

• To systematically characterize alterations in clock genes across 32 distinct cancer types.
• To investigate the clinical relevance of these clock gene alterations in cancer.

Main Methods:

• Analysis of The Cancer Genome Atlas, Cancer Therapeutics Response Portal, and The Genomics of Drug Sensitivity in Cancer databases.
• Systematic characterization of clock gene expression alterations.
• Integration of co-expression, protein-protein interaction, and ChIP-seq data to identify gene interactions.

Main Results:

• Clock gene expression alterations are linked to oncogenic pathways, patient survival, tumor stage, and cancer subtypes across multiple cancer types.
• Significant differences in clock gene and whole-genome gene correlations were observed between cancerous and normal tissues.
• Interactions between clock genes and clinically actionable genes were identified.
• Clock gene expression correlates with anti-cancer drug sensitivity in cancer cell lines.

Conclusions:

• This study offers a comprehensive analysis of the circadian clock's role in diverse cancer types.
• The findings highlight the potential clinical utility of cancer chronotherapy by linking clock gene alterations to patient outcomes and drug responses.